Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the ...

BofA Securities upgrades shares to Buy from Hold with an $860 price target, up sharply from $627.

Regeneron Pharmaceuticals has recently drawn renewed attention as investment funds, Wall Street analysts, and industry observers highlight its broad biologics pipeline, disciplined capital allocation, ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.62% to $741.92 Thursday, on what proved to be an all-around favorable ...

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 96.18 with a total volume of 127.00.

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

The story around Regeneron is shifting, and one big player just made it official.

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results. Several ...

This was the stock's fourth consecutive day of losses.